Search

Refine your search

Tags
Jurisdiction

650 results found

Article

Foley & Lardner LLP | USA | 6 Feb 2018

PTAB Enters Sua Sponte Patent Eligibility Rejections

We’ve written previously about ex parte decisions of the Patent Trial and Appeal Board (PTAB) affirming patent eligibility rejections that seem to be…
Article

Foley & Lardner LLP | USA | 30 Jan 2018

Federal Circuit Emphasizes Need For Reasonable Expectation Of Success

In Genzyme Corp. v. Dr. Reddy’s Labs. Ltd., the Federal Circuit affirmed the district court decision upholding Genzyme’s Orange Book listed patent for…
Article

Foley & Lardner LLP | USA | 23 Jan 2018

Three Things To Know About Rule 130 Declarations

A few weeks ago I joined Kathleen Fonda, Ph.D., J.D., Senior Legal Advisor in the USPTO’s Office of Patent Legal Administration, and Gary Ganzi, J.D…
Article

Foley & Lardner LLP | USA | 18 Jan 2018

How Much Is That Issue Fee Payment In The Window?

A new USPTO fee schedule took effect on January 16, 2018, which usually means that all fees must be paid at the new (higher) rate. However, thanks to…
Article

Foley & Lardner LLP | USA | 9 Jan 2018

Prosecution History Informs Claim Meaning Even Without Unmistakable Disclaimer

Although non-precedential, the Federal Circuit decision in Aptalis Pharmatech, Inc. v. Apotex Inc. is worth a read to see how the court “tiptoes” the…
Article

Foley & Lardner LLP | USA | 2 Jan 2018

New Year's Resolutions For The U.S. Patent System

It’s that time of year when we make resolutions to improve our health, our relationships, our careers, or other areas of our lives. I’m not starting…
Article

Foley & Lardner LLP | USA | 19 Dec 2017

Federal Circuit Finds Preemption Of State Law Penalty For Sitting Out Biosimilar Patent Dance

The Federal Circuit has issued its final decision in the biosimilar patent litigation between Amgen and Sandoz over the first product to be approved…
Article

Foley & Lardner LLP | USA | 19 Dec 2017

Federal Circuit Finds Preemption Of State Law Penalty For Sitting Out Biosimilar Patent Dance

The Federal Circuit has issued its final decision in the biosimilar patent litigation between Amgen and Sandoz over the first product to be approved…
Article

Foley & Lardner LLP | USA | 28 Nov 2017

Canada Provides More Guidance On Patent Eligibility Of Diagnostic Method Claims

While the patent eligibility of diagnostic method claims remains questionable in the United States, the Canadian Intellectual Property Office has…
Article

Foley & Lardner LLP | USA | 20 Nov 2017

USPTO Patent Fees To Go Up January 2018

While Congress is trying to pass a tax reform bill that would cut corporate taxes, USPTO patent fees will increase effective January 16, 2018. The 72%…
Previous page 1 2 3 ...